In comparison to IDH‐wildtype gliomas of the same grade, IDH‐mutant gliomas are associated with a rather favorable prognosis [10], and they occur in ~ 80% of WHO grade II/III gliomas [11]. The gene discussed is IDH2; the disease is central nervous system cancer.